Drugs.com - Monthly Update May 2026

In this May 2026 Monthly Update edition, we cover several new FDA approvals and a major prescription-to-OTC switch expanding therapeutic options.Veppanu (vepdegestrant): The first PROTAC (PROteolysis TArgeting Chimera) therapy to be approved for ESR1-mutated, ER+/HER2- advanced or metastatic breast cancer based on strong progression-free survival clinical data.Trimbow (beclomethasone dipropionate/formoterol fumarate/glycopyrrolate): A triple-combination inhalation aerosol approved for the long-term maintenance treatment of adult asthma.Xocova (ensitrelvir): The first oral antiviral tablet indicated for post-exposure prophylaxis (PEP) to prevent COVID-19 following exposure.Baxfendy (baxdrostat): A first-in-class oral aldosterone synthase inhibitor approved to treat uncontrolled hypertension in combination with other agents.Differin Epiduo Acne Gel (adapalene/benzoyl peroxide): A prescription combination acne treatment newly approved for over-the-counter (OTC) use.Zaynich (cefepime/zidebactam): An intravenous antibiotic approved for adults suffering from complicated urinary tract infections and pyelonephritis.Immgolis (golimumab-sldi): The first interchangeable biosimilar to Simponi approved for adult rheumatoid arthritis and ulcerative colitis.Chapters:(00:20) - Intro (00:58) - Veppanu (01:58) - Trimbow (03:13) - Xocova (04:28) - Zaynich (05:31) - Baxfendy (06:28) - Differin Epiduo Acne Gel (07:28) - Immgolis (08:06) - Outro Follow Drugs.com:X, Facebook, YouTubeSign up to our newslettersDownload the app